We are live on
!
Find out more
BBA
Baker Bros. Advisors Portfolio holdings
AUM
$20B
1-Year Est. Return
154.41%
This Fund
S&P 500
This Quarter
Est. Return
+22.23%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$20B
AUM Growth
+$2.54B
(+15%)
Cap. Flow
+$128M
Cap. Flow
% of AUM
0.64%
Top 10 Holdings %
Top 10 Hldgs %
72.82%
Holding
92
New
8
Increased
16
Reduced
7
Closed
9
Avg Time Held
14.2
quarters
Top 10 Avg Time Held
18.7
quarters
Top 20 Avg Time Held
13.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$276M |
| 2 |
Insmed
INSM
|
+$166M |
| 3 |
IDEAYA Biosciences
IDYA
|
+$32.6M |
| 4 |
Faeth Therapeutics
FTH
|
+$29.8M |
| 5 |
Relay Therapeutics
RLAY
|
+$24.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$99.1M |
| 2 |
Abivax
ABVX
|
+$97.5M |
| 3 |
Summit Therapeutics
SMMT
|
+$63.9M |
| 4 |
Spyre Therapeutics
SYRE
|
+$50.4M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$26.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.65% |
| 2 | Miscellaneous | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Generate Biomedicines
GENB
$1.73B
| $24M | 0.12% |
1,423,602
| – | – |
2026 Q1
1 quarter
|
|
52
DBV Technologies S.A. American Depositary Shares
DBVT
$583M
| $24M | 0.12% |
1,461,425
| – | – |
2014 Q4
46 quarters
|
|
53
Xenon Pharmaceuticals
XENE
$3.44B
| $22.3M | 0.11% |
370,208
| – | – |
2020 Q2
24 quarters
|
|
54
Tectonic Therapeutic
TECX
$427M
| $20.9M | 0.1% |
607,788
| – | – |
2025 Q1
5 quarters
|
|
55
Cerus
CERS
$453M
| $18.7M | 0.09% |
6,395,431
-3,612,914
| -36% | -$8.76M |
2013 Q2
52 quarters
|
|
56
CytomX Therapeutics
CTMX
$516M
| $18.7M | 0.09% |
4,975,826
| – | – |
2025 Q2
4 quarters
|
|
57
Dyne Therapeutics
DYN
$2.94B
| $18.1M | 0.09% |
813,449
| – | – |
2025 Q4
2 quarters
|
|
58
Cytokinetics
CYTK
$8.7B
| $18M | 0.09% |
+211,267
| New | +$15.2M |
2026 Q2
0 quarters
|
|
59
Xencor
XNCR
$1.84B
| $17.7M | 0.09% |
1,102,106
| – | – |
2022 Q4
14 quarters
|
|
60
Sionna Therapeutics
SION
$207M
| $17.6M | 0.09% |
400,000
| – | – |
2025 Q1
5 quarters
|
|
61
Intellia Therapeutics
NTLA
$1.7B
| $15.7M | 0.08% |
+930,232
| New | +$13M |
2026 Q2
0 quarters
|
|
|
PBLS
62
Parabilis Medicines Inc
PBLS
$3.47B
| $13.7M | 0.07% |
+500,000
| New | +$13.8M |
2026 Q2
0 quarters
|
|
63
MapLight Therapeutics
MPLT
$469M
| $13.1M | 0.07% |
364,705
| – | – |
2025 Q4
2 quarters
|
|
64
Avalyn Pharma
AVLN
$1.08B
| $11.5M | 0.06% |
+350,000
| New | +$10.1M |
2026 Q2
0 quarters
|
|
65
Evommune Inc
EVMN
$219M
| $11.3M | 0.06% |
847,390
| – | – |
2026 Q1
1 quarter
|
|
66
BioNTech
BNTX
$22.9B
| $11.1M | 0.06% |
119,743
| – | – |
2024 Q4
6 quarters
|
|
67
Tango Therapeutics
TNGX
$4.01B
| $10.4M | 0.05% |
+333,333
| New | +$8.24M |
2026 Q2
0 quarters
|
|
68
Avalo Therapeutics
AVTX
$691M
| $10.2M | 0.05% |
+550,000
| New | +$8.69M |
2026 Q2
0 quarters
|
|
69
Sera Prognostics
SERA
$80.1M
| $10M | 0.05% |
5,498,170
| – | – |
2021 Q3
19 quarters
|
|
70
Verastem
VSTM
$740M
| $9.55M | 0.05% |
2,499,338
+1,914,581
| +327% | +$9.26M |
2026 Q1
1 quarter
|
|
71
Sagimet Biosciences
SGMT
$606M
| $7.37M | 0.04% |
952,996
| – | – |
2023 Q3
11 quarters
|
|
72
Eikon Therapeutics
EIKN
$385M
| $7.25M | 0.04% |
555,555
| – | – |
2026 Q1
1 quarter
|
|
73
LB Pharmaceuticals
LBRX
$1.15B
| $6.49M | 0.03% |
200,000
| – | – |
2025 Q3
3 quarters
|
|
74
vTv Therapeutics
VTVT
$121M
| $5.58M | 0.03% |
148,314
| – | – |
2024 Q1
9 quarters
|
|
75
Wave Life Sciences
WVE
$631M
| $4.78M | 0.02% |
822,638
| – | – |
2024 Q3
7 quarters
|
|
Similar funds
ASRS
FWIA
CWP
SFA
MGP
JAM
Baker Bros. Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Baker Bros. Advisors held 92 positions worth $20B, up 15% from $17.4B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Baker Bros. Advisors's Q2 2026 filing shows 8 new, 16 increased, 7 reduced and 9 closed positions. Its largest new stake was Faeth Therapeutics: 1,286,411 shares worth $32.2M. The largest sale was Edgewise Therapeutics, an estimated $99.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- Baker Bros. Advisors's largest Q2 2026 buy was Faeth Therapeutics: 1,286,411 shares worth $32.2M.
- Baker Bros. Advisors added most to Revolution Medicines in Q2 2026, an estimated $276M increase.
- Baker Bros. Advisors's biggest Q2 2026 reduction was Edgewise Therapeutics, cutting an estimated $99.1M.
- Baker Bros. Advisors fully exited Abivax in Q2 2026, selling an estimated $97.5M.
- Baker Bros. Advisors's ten largest holdings make up 73% of its $20B portfolio in Q2 2026.
- Baker Bros. Advisors opened 8 new positions and closed 9 in Q2 2026.
- Baker Bros. Advisors's portfolio value rose 15% quarter-over-quarter to $20B.
Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.